Movement Alert｜SKB BIO Rises 3.78% in Regular Trading, Core TROP2 ADC New Indication Application Accepted by NMPA

Market Focus07-31 10:05

On July 31, SKB BIO rose 3.78% in regular trading, trading at 498.4 HKD/share, with turnover of approximately HKD 68.16 million.

On the news front, the company announced on July 30 that a new indication application for its core product sacituzumab tirumotecan (TROP2 ADC) for first-line treatment of recurrent or metastatic triple-negative breast cancer with PD-L1 CPS less than 10 or prior PD-1/PD-L1 inhibitor exposure has been accepted by NMPA and included in the priority review program. This marks the sixth indication application accepted for the product, which already has four approved indications in China and is the first TROP2 ADC globally approved for a lung cancer indication.

Additionally, partner Merck recently initiated a Phase II clinical study (MK-2010-003) evaluating sacituzumab tirumotecan combined with PD-1/VEGF bispecific antibody MK-2010 in advanced solid tumors, further expanding the combination therapy pipeline and signaling deeper global collaboration.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1113507032?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 10:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113507032","market":"us","top_or_hot":-1,"title":"Movement Alert｜SKB BIO Rises 3.78% in Regular Trading, Core TROP2 ADC New Indication Application Accepted by NMPA","media":"Market Focus","content":"<p><p>On July 31, SKB BIO rose 3.78% in regular trading, trading at 498.4 HKD/share, with turnover of approximately HKD 68.16 million.</p><p>On the news front, the company announced on July 30 that a new indication application for its core product sacituzumab tirumotecan (TROP2 ADC) for first-line treatment of recurrent or metastatic triple-negative breast cancer with PD-L1 CPS less than 10 or prior PD-1/PD-L1 inhibitor exposure has been accepted by NMPA and included in the priority review program. This marks the sixth indication application accepted for the product, which already has four approved indications in China and is the first TROP2 ADC globally approved for a lung cancer indication.</p><p>Additionally, partner Merck recently initiated a Phase II clinical study (MK-2010-003) evaluating sacituzumab tirumotecan combined with PD-1/VEGF bispecific antibody MK-2010 in advanced solid tumors, further expanding the combination therapy pipeline and signaling deeper global collaboration.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜SKB BIO Rises 3.78% in Regular Trading, Core TROP2 ADC New Indication Application Accepted by NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜SKB BIO Rises 3.78% in Regular Trading, Core TROP2 ADC New Indication Application Accepted by NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-31 10:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 31, SKB BIO rose 3.78% in regular trading, trading at 498.4 HKD/share, with turnover of approximately HKD 68.16 million.</p><p>On the news front, the company announced on July 30 that a new indication application for its core product sacituzumab tirumotecan (TROP2 ADC) for first-line treatment of recurrent or metastatic triple-negative breast cancer with PD-L1 CPS less than 10 or prior PD-1/PD-L1 inhibitor exposure has been accepted by NMPA and included in the priority review program. This marks the sixth indication application accepted for the product, which already has four approved indications in China and is the first TROP2 ADC globally approved for a lung cancer indication.</p><p>Additionally, partner Merck recently initiated a Phase II clinical study (MK-2010-003) evaluating sacituzumab tirumotecan combined with PD-1/VEGF bispecific antibody MK-2010 in advanced solid tumors, further expanding the combination therapy pipeline and signaling deeper global collaboration.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1113507032","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113507032","pubTimestamp":1785463526,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 31, SKB BIO rose 3.78% in regular trading, trading at 498.4 HKD/share, with turnover of approximately HKD 68.16 million.On the news front, the company announced on July 30 that a new...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"走势提醒|SKB生物常规交易涨3.78%，核心TROP2 ADC新适应症申请获国家药监局受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"On July 31, SKB BIO rose 3.78% in regular trading, trading at 498.4 HKD/share, with turnover of approximately HKD 68.16 million.On the news front, the company announced on July 30 that a new indication application for its core product sacituzumab tirumotecan (TROP2 ADC) for first-line treatment of recurrent or metastatic triple-negative breast cancer with PD-L1 CPS less than 10 or prior PD-1/PD-L1 inhibitor exposure has been accepted by NMPA and included in the priority review program. This marks the sixth indication application accepted for the product, which already has four approved indications in China and is the first TROP2 ADC globally approved for a lung cancer indication.Additionally, partner Merck recently initiated a Phase II clinical study (MK-2010-003) evaluating sacituzumab tirumotecan combined with PD-1/VEGF bispecific antibody MK-2010 in advanced solid tumors, further expanding the combination therapy pipeline and signaling deeper global collaboration.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1113507032","isCrawlerRequest":true}